Overview
Announcements

Ordinary Index Rebalancing in the Solactive Diabetes Performance-Index | September 2019

In the ordinary rebalance the following composition will be implemented:

ABBOTT LABORATORIES
APPLIED THERAPEUTICS INC
BRIGHTER AB
CONVATEC GROUP PLC
DEXCOM INC
ELI LILLY & CO
INSULET CORP
KALVISTA PHARMACEUTICALS INC
LEXICON PHARMACEUTICALS INC
Livongo Health Inc
MANNKIND CORP
NOVO NORDISK AS CLASS B
PDL BIOPHARMA INC
POXEL SA
SENSEONICS HOLDINGS INC
TANDEM DIABETES CARE INC
YPSOMED HOLDING AG
ZEALAND PHARMA A/S